Patent Waiver Proposals Under WTO Legality

Introduction

Patent waiver proposals under the World Trade Organization (WTO) concern whether member states may temporarily suspend or relax intellectual property obligations to address public health emergencies and ensure access to essential medicines, vaccines, and medical technologies. The central legal instrument is the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). A waiver does not automatically cancel patents; it permits members, within an agreed scope, to depart from specified international obligations.

Legal Framework Under TRIPS

Articles 7 and 8 of TRIPS recognize the objectives of technological innovation, technology transfer, social welfare, and measures necessary to protect public health. Article 28 grants patent holders exclusive rights, while Article 31 permits use of patented inventions without the owner’s consent, subject to safeguards such as adequate remuneration and limits on the scope and duration of authorization. Article 31bis provides a mechanism for producing and exporting pharmaceutical products to countries lacking sufficient manufacturing capacity.

TRIPS and public health

+1

Article IX of the Marrakesh Agreement establishing the WTO empowers the Ministerial Conference and General Council, in specified circumstances, to grant waivers from WTO obligations. Therefore, a WTO-wide waiver can be legally permissible if adopted through the appropriate institutional process. Its scope depends on the exact decision adopted; a proposal alone does not create a binding waiver.

COVID-19 Waiver Proposal

In October 2020, India and South Africa proposed waiving certain TRIPS obligations relating to copyright, industrial designs, patents, and undisclosed information to help prevent, contain, and treat COVID-19. Supporters argued that intellectual property restrictions could impede affordable production and equitable access. Opponents raised concerns about weakening innovation incentives and argued that existing compulsory-licensing mechanisms could address many barriers.

Ministerial conferences - MC12 briefing note

+1

The WTO’s Twelfth Ministerial Conference adopted the Ministerial Decision on the TRIPS Agreement on 17 June 2022. The adopted decision was narrower than the original proposal: it focused on COVID-19 vaccines, clarified certain options under Article 31, and relaxed the Article 31(f) domestic-supply restriction for eligible members under specified conditions. It did not establish a general waiver for all medicines, diagnostics, or therapeutics. WTO members did not reach consensus on extending the decision to COVID-19 diagnostics and therapeutics.

Health Justice Initiative (HJI)

+1

Relevant Case Laws

1. ** Doha Declaration on the TRIPS Agreement and Public Health (2001):** Although not a court judgment, this is a foundational WTO instrument. It affirmed that TRIPS should be interpreted and implemented in a manner supportive of public health and confirmed members’ freedom to determine the grounds for compulsory licensing.

The separate Doha Declaration explained

+1

2. ** Canada — Patent Protection of Pharmaceutical Products (WT/DS114, 2000):** The WTO panel examined whether Canada’s patent-law exceptions complied with TRIPS Article 30. It accepted a limited regulatory-review exception but rejected a broader stockpiling exception. The decision demonstrates that a member cannot assume that every domestic exception is TRIPS-compliant; the legal conditions must be satisfied unless a valid waiver applies.

Springer Nature Link

+1

3. ** Bayer Corporation v. Union of India (Bombay High Court, 2014):** The court upheld the compulsory licence for Bayer’s cancer drug Nexavar granted to Natco Pharma. The decision illustrates how Indian law can balance patent protection against affordability and public access, without requiring a general international patent waiver.

IndiaCode

+1

Position Under Indian Law

India’s Patents Act, 1970, provides domestic mechanisms for compulsory licensing. Section 84 permits a licence where public requirements are unmet, the invention is not reasonably affordable, or the patent is not worked in India. Section 92 provides a special mechanism for national emergencies, extreme urgency, and public non-commercial use. These provisions operate alongside India’s WTO obligations and do not depend on the adoption of a general TRIPS waiver.

Government of India

+1

Conclusion

Patent waiver proposals can be lawful under WTO law when adopted through the proper waiver procedure and limited by their terms. The 2022 COVID-19 decision demonstrates that WTO members can authorize carefully defined departures from patent obligations in exceptional circumstances. However, a proposal is not itself a waiver, and the decision did not suspend patent protection across all medical products. The continuing legal challenge is to balance innovation incentives and patent-holder interests with equitable access to essential technologies, especially during global health emergencies.